Galera Therapeutics converts all Series B Preferred Stock into 42.8M common shares

Galera Therapeutics, Inc.

Converted 42,839.11 Series B preferred shares into 42,839,103 common shares on May 15, 2026.
No fractional shares were issued; holders will receive cash in lieu of fractional shares.
After conversion, no shares of Series B Preferred Stock remain outstanding.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.